LXRX News and Press, Lexicon Pharmaceuticals Inc. From 10/31/22

THE WOODLANDS, Texas, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF and SCORED Phase 3 outcomes studies of its investigational sotagliflozin product at the Ame...

THE WOODLANDS, Texas, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug LX9211 will be delivered virtually during the World Brain Disorders and Neuroscience Su...

Data presented at the Heart Failure Society of America annual scientific meeting New analysis adds to growing body of evidence in support of the use of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, in the treatment of heart failure THE WOODLAN...

Summary Lexicon's sotagliflozin, armed with strong data, will have a PDUFA in May 2023. Earlier rejections in T1DM do not have a bearing on this T2DM NDA. I expect an approval in 2023, which may boost up the stock considerably, given the large market potential. When ...

Poster and Oral Presentation at PAINWeek Describing a Novel Mechanism of Action for Neuropathic Pain Poster at International Association for the Study of Pain (IASP) World Congress on Pain Describing Design Elements of the RELIEF-DPN-1 Study Podium Presentation...

Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies Recent Publication in the Journal Diabetes Care Evaluates Metabolic, Intestinal and Cardiovascular Effects in a...

The shares of Woodlands, Texas-based biotech Lexicon Pharmaceuticals ( NASDAQ: LXRX ) gained ~15% after Piper Sandler launched its coverage with an Overweight recommendation citing the “blockbuster potential” for two of its assets. The analyst Yasmeen Rahim...

Neptune Wellness Solutions ( NEPT ) +48% . ADDvantage Technologies Group ( AEY ) +33% Technologies GAAP EPS of $0.07, revenue of $27.79M. Larimar Therapeutics ( LRMR ) +31% on plans to resolve clinical hold on lead asset. Twin Vee Powercats ...

Over the past few days, there have been some monster moves across a number of Russell 3,000 stocks. Taking a look at the Russell 3,000 members that had at least been cut in half from the time of the index’s high on January 3rd through the low on June 16th, followed by a rally o...

THE WOODLANDS, Texas, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the issuance and sale of an additional 2,526,540 shares of its common stock, par value $0.001 (the “ Common Stock ”)...